HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...
Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR ...
Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
Bristol Myers Squibb's phase 3 trial of Opdivo for head and neck cancer post surgery met primary endpoint, showing improved disease-free survival. Read more here.
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback